ALXO vs. LBPH, IRON, PRAX, EOLS, ARCT, TNGX, DNTH, ZNTL, PRTC, and AUPH
Should you be buying ALX Oncology stock or one of its competitors? The main competitors of ALX Oncology include Longboard Pharmaceuticals (LBPH), Disc Medicine (IRON), Praxis Precision Medicines (PRAX), Evolus (EOLS), Arcturus Therapeutics (ARCT), Tango Therapeutics (TNGX), Dianthus Therapeutics (DNTH), Zentalis Pharmaceuticals (ZNTL), PureTech Health (PRTC), and Aurinia Pharmaceuticals (AUPH). These companies are all part of the "pharmaceutical preparations" industry.
ALX Oncology (NASDAQ:ALXO) and Longboard Pharmaceuticals (NASDAQ:LBPH) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, community ranking, institutional ownership, risk, profitability, media sentiment, valuation, analyst recommendations and earnings.
ALX Oncology has a beta of 1.3, indicating that its share price is 30% more volatile than the S&P 500. Comparatively, Longboard Pharmaceuticals has a beta of 1.25, indicating that its share price is 25% more volatile than the S&P 500.
In the previous week, ALX Oncology had 6 more articles in the media than Longboard Pharmaceuticals. MarketBeat recorded 8 mentions for ALX Oncology and 2 mentions for Longboard Pharmaceuticals. ALX Oncology's average media sentiment score of 0.78 beat Longboard Pharmaceuticals' score of 0.28 indicating that ALX Oncology is being referred to more favorably in the media.
ALX Oncology currently has a consensus price target of $18.83, indicating a potential upside of 32.54%. Longboard Pharmaceuticals has a consensus price target of $43.67, indicating a potential upside of 111.05%. Given Longboard Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Longboard Pharmaceuticals is more favorable than ALX Oncology.
Longboard Pharmaceuticals is trading at a lower price-to-earnings ratio than ALX Oncology, indicating that it is currently the more affordable of the two stocks.
Longboard Pharmaceuticals received 4 more outperform votes than ALX Oncology when rated by MarketBeat users. Likewise, 73.33% of users gave Longboard Pharmaceuticals an outperform vote while only 61.54% of users gave ALX Oncology an outperform vote.
Longboard Pharmaceuticals' return on equity of -49.87% beat ALX Oncology's return on equity.
98.0% of ALX Oncology shares are owned by institutional investors. Comparatively, 63.3% of Longboard Pharmaceuticals shares are owned by institutional investors. 33.4% of ALX Oncology shares are owned by company insiders. Comparatively, 4.6% of Longboard Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Summary
Longboard Pharmaceuticals beats ALX Oncology on 9 of the 15 factors compared between the two stocks.
Get ALX Oncology News Delivered to You Automatically
Sign up to receive the latest news and ratings for ALXO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ALXO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ALX Oncology Competitors List
Related Companies and Tools
